JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB6755

Rabbit Anti-Human IgG H&L (FITC)

Rabbit Anti-Human IgG H&L (FITC)

Be the first to review this product! Submit a review

|

(4 Publications)

Suitable for IHC-Fr, ELISA, IM, Flow Cyt, ICC/IF. Cited in 4 publications.

別名を表示する

Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1, Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, IGHG4, Immunoglobulin heavy constant gamma 3, HDC, Heavy chain disease protein, Ig gamma-3 chain C region, IGHG3, Immunoglobulin heavy constant gamma 2, Ig gamma-2 chain C region, Ig gamma-2 chain C region DOT, Ig gamma-2 chain C region TIL, Ig gamma-2 chain C region ZIE, IGHG2

Key facts

宿主種

Rabbit

ターゲット種

Human

ターゲットアイソタイプ

IgG

ターゲット特異性

Heavy & Light chains

最小限の交差反応性
血清吸着処理済み

No

標識

FITC

励起波長/蛍光波長

Ex: 495nm, Em: 519nm

アプリケーション

IM, ICC/IF, IHC-Fr, ELISA, Flow Cyt

applications

クローン性

Polyclonal

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "IHC-Fr": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"", "notes":"<p></p>" }, "ELISA": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"1/10000 - 1/50000", "notes":"<p></p>" }, "IM": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"1/1000 - 1/5000", "notes":"<p></p>" }, "Flow Cyt": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"1/500 - 1/2500", "notes":"<p></p>" }, "ICC/IF": { "reactivity":"NO_EXPERIMENTAL_DATA_EXPECTED_TO_REACT", "dilution-info":"1/1000 - 1/5000", "notes":"<p></p>" } } }

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification
精製に関する特記事項
This product was prepared from monospecific antiserum by immunoaffinity chromatography using Human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities.
バッファー組成
Preservative: 0.01% Sodium azide Constituents: 1% BSA, 0.88% Sodium chloride, 0.424% Potassium phosphate solution
出荷温度
Blue Ice
短期保存温度
+4°C
長期保存温度
+4°C

製品プロトコール

ターゲットの情報

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region) (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. Each Ig molecule has two antigen-binding sites with remarkable affinity for a particular antigen due to V-(D)-J rearrangement, somatic hypermutations and affinity maturation of the variable domains upon antigen exposure (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region defines the Ig isotype that perform distinct sets of effector functions. B cells diversify and rearrange their Ig constant regions through class-switch recombination, a process by which the constant region is switched from one Ig isotype to another, namely from IgM and IgD to IgG, IgA and IgE (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region of Ig gamma-1 (IgG1) isotype interacts (via the fragment crystallizable, Fc) with receptors on innate immune cells and the complement system to mediate humoral effector functions, including antibody-dependent cellular cytotoxicity or phagocytosis, complement-dependent cytotoxicity and inflammatory responses.
See full target information IGHG1

追加のターゲット

IGHG3,IGHG2,IGHG4

文献 (4)

Recent publications for all applications. Explore the full list and refine your search

Vaccines 13: PubMed40573956

2025

Highly Effective mRNA-LNP Vaccine Against Respiratory Syncytial Virus (RSV) in Multiple Models.

Applications

Unspecified application

Species

Unspecified reactive species

Huarong Bai,Xueliang Yu,Yue Gao,Qin Li,Baigang Wen,Rongkuan Hu

Oncology letters 24:347 PubMed36072001

2022

Lidocaine inhibits the proliferation and migration of endometrial cancer cells, and promotes apoptosis by inducing autophagy.

Applications

Unspecified application

Species

Unspecified reactive species

Dingde Long,Yayu Chen,Liangchao Qu,Yang Dong

Biochemical pharmacology 203:115187 PubMed35878796

2022

Human 5-lipoxygenase regulates transcription by association to euchromatin.

Applications

Unspecified application

Species

Unspecified reactive species

Marius Kreiß,Julia H Oberlis,Sabine Seuter,Iris Bischoff-Kont,Duran Sürün,Dominique Thomas,Tamara Göbel,Tobias Schmid,Olof Rådmark,Ralf P Brandes,Robert Fürst,Ann-Kathrin Häfner,Dieter Steinhilber

Oncology letters 18:6787-6794 PubMed31788123

2019

Long noncoding RNA IRAIN acts as tumor suppressor via miR-125b in multiple myeloma.

Applications

Unspecified application

Species

Unspecified reactive species

Yanxia Jiang,Jian Chen,Guoan Chen
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com